349P Comparison of short- and long-term proteomic response to the fast skeletal myosin inhibitor, sevasemten (EDG-5506), in Becker muscular dystrophy (BMD)
B. Barthel(Healthwise), Alan J. Russell(Healthwise), Kevin M. Koch(Hospital for Special Surgery), J. Donovan(Healthwise), Marc Evanchik(Fluidigm (United States)), H. Phan(Rare Disease Therapeutics (United States)), L. Thaler(Emory University), Mary Madden(University of York), Sarah Collins
Cited by 0
Related Papers
Hyperglycemia: An Independent Marker of In-Hospital Mortality in Patients with Undiagnosed Diabetes
|The Journal of Clinical Endocrinology & Metabolism|2002|2.1k
A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice
|Science|2016|710
Beware Zombies and Unicorns: Toward Critical Patient and Public Involvement in Health Research in a Neoliberal Context
|Frontiers in Sociology|2017|192
Resiliency and Vulnerability in the HER2-HER3 Tumorigenic Driver
|Science Translational Medicine|2010|185
Newborn screening for spinal muscular atrophy: Anticipating an imminent need
|Seminars in Perinatology|2015|79